vs
ASP Isotopes Inc.（ASPI）与CVRx, Inc.（CVRX）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是CVRx, Inc.的1.0倍（$16.7M vs $16.0M），ASP Isotopes Inc.同比增速更快（1295.7% vs 4.4%），CVRx, Inc.自由现金流更多（$-9.8M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
CVRx, Inc.是一家处于商业化阶段的医疗科技企业，专注于慢性心血管疾病神经调节疗法的研发与商业化，旗舰产品Barostim系统用于治疗心力衰竭和难治性高血压，核心市场覆盖北美、欧洲，服务对常规药物治疗应答不佳的患者。
ASPI vs CVRX — 直观对比
营收规模更大
ASPI
是对方的1.0倍
$16.0M
营收增速更快
ASPI
高出1291.2%
4.4%
自由现金流更多
CVRX
多$37.6M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $16.0M |
| 净利润 | — | $-11.9M |
| 毛利率 | 12.5% | 86.3% |
| 营业利润率 | — | -69.8% |
| 净利率 | — | -74.5% |
| 营收同比 | 1295.7% | 4.4% |
| 净利润同比 | -586.8% | -12.0% |
| 每股收益（稀释后） | — | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPICVRX
| Q4 25 | $16.7M | $16.0M | ||
| Q3 25 | $4.9M | $14.7M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $12.3M | ||
| Q4 24 | — | $15.3M | ||
| Q3 24 | — | $13.4M | ||
| Q2 24 | — | $11.8M | ||
| Q1 24 | — | $10.8M |
净利润ASPICVRX
| Q4 25 | — | $-11.9M | ||
| Q3 25 | $-12.9M | $-12.9M | ||
| Q2 25 | — | $-14.7M | ||
| Q1 25 | — | $-13.8M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | — | $-13.1M | ||
| Q2 24 | — | $-14.0M | ||
| Q1 24 | — | $-22.2M |
毛利率ASPICVRX
| Q4 25 | 12.5% | 86.3% | ||
| Q3 25 | 8.7% | 86.8% | ||
| Q2 25 | — | 84.3% | ||
| Q1 25 | — | 83.5% | ||
| Q4 24 | — | 83.2% | ||
| Q3 24 | — | 83.2% | ||
| Q2 24 | — | 83.9% | ||
| Q1 24 | — | 85.0% |
营业利润率ASPICVRX
| Q4 25 | — | -69.8% | ||
| Q3 25 | -306.1% | -83.5% | ||
| Q2 25 | — | -105.8% | ||
| Q1 25 | — | -108.8% | ||
| Q4 24 | — | -67.0% | ||
| Q3 24 | — | -97.3% | ||
| Q2 24 | — | -118.3% | ||
| Q1 24 | — | -206.4% |
净利率ASPICVRX
| Q4 25 | — | -74.5% | ||
| Q3 25 | -263.7% | -87.6% | ||
| Q2 25 | — | -108.4% | ||
| Q1 25 | — | -111.5% | ||
| Q4 24 | — | -69.4% | ||
| Q3 24 | — | -98.0% | ||
| Q2 24 | — | -118.8% | ||
| Q1 24 | — | -206.0% |
每股收益（稀释后）ASPICVRX
| Q4 25 | — | $-0.45 | ||
| Q3 25 | $-0.15 | $-0.49 | ||
| Q2 25 | — | $-0.57 | ||
| Q1 25 | — | $-0.53 | ||
| Q4 24 | — | $-0.39 | ||
| Q3 24 | — | $-0.57 | ||
| Q2 24 | — | $-0.65 | ||
| Q1 24 | — | $-1.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $75.7M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $39.3M |
| 总资产 | $498.0M | $104.8M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPICVRX
| Q4 25 | $333.3M | $75.7M | ||
| Q3 25 | $113.9M | $85.1M | ||
| Q2 25 | — | $95.0M | ||
| Q1 25 | — | $102.7M | ||
| Q4 24 | — | $105.9M | ||
| Q3 24 | — | $100.2M | ||
| Q2 24 | — | $70.4M | ||
| Q1 24 | — | $80.1M |
总债务ASPICVRX
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ASPICVRX
| Q4 25 | $204.2M | $39.3M | ||
| Q3 25 | $74.1M | $48.1M | ||
| Q2 25 | — | $57.9M | ||
| Q1 25 | — | $71.1M | ||
| Q4 24 | — | $71.1M | ||
| Q3 24 | — | $65.2M | ||
| Q2 24 | — | $55.2M | ||
| Q1 24 | — | $66.3M |
总资产ASPICVRX
| Q4 25 | $498.0M | $104.8M | ||
| Q3 25 | $225.9M | $111.3M | ||
| Q2 25 | — | $119.6M | ||
| Q1 25 | — | $129.6M | ||
| Q4 24 | — | $133.4M | ||
| Q3 24 | — | $127.7M | ||
| Q2 24 | — | $96.0M | ||
| Q1 24 | — | $106.2M |
负债/权益比ASPICVRX
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-9.8M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $-9.8M |
| 自由现金流率自由现金流/营收 | -284.7% | -61.3% |
| 资本支出强度资本支出/营收 | 57.9% | 0.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-40.8M |
8季度趋势，按日历期对齐
经营现金流ASPICVRX
| Q4 25 | $-37.8M | $-9.8M | ||
| Q3 25 | $-8.9M | $-9.7M | ||
| Q2 25 | — | $-7.9M | ||
| Q1 25 | — | $-12.8M | ||
| Q4 24 | — | $-8.0M | ||
| Q3 24 | — | $-10.4M | ||
| Q2 24 | — | $-9.8M | ||
| Q1 24 | — | $-10.9M |
自由现金流ASPICVRX
| Q4 25 | $-47.4M | $-9.8M | ||
| Q3 25 | $-12.0M | $-10.0M | ||
| Q2 25 | — | $-8.0M | ||
| Q1 25 | — | $-12.9M | ||
| Q4 24 | — | $-8.1M | ||
| Q3 24 | — | $-10.4M | ||
| Q2 24 | — | $-10.2M | ||
| Q1 24 | — | $-11.8M |
自由现金流率ASPICVRX
| Q4 25 | -284.7% | -61.3% | ||
| Q3 25 | -245.5% | -68.1% | ||
| Q2 25 | — | -59.2% | ||
| Q1 25 | — | -104.3% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -78.1% | ||
| Q2 24 | — | -86.3% | ||
| Q1 24 | — | -109.7% |
资本支出强度ASPICVRX
| Q4 25 | 57.9% | 0.4% | ||
| Q3 25 | 64.4% | 2.0% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 8.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
CVRX
| US | $14.9M | 93% |
| Other | $1.1M | 7% |
